FDA Mulls Approach To Switches In Context Of Galderma's Acne Drug OTC Bid

FDA's OTC division uses the NDAC meeting on Galderma's Differin Gel switch proposal to ask for the advisory committee's input on evaluating future NDAs for other switches that could introduce new risks to the OTC space.